Myriad Genetics (MYGN) Stock Statistics & Valuation Metrics

Myriad Genetics has a market cap or net worth of $615.02M. The enterprise value is $571.38M.

Myriad Genetics has 93,044,624 shares outstanding. The number of shares has decreased by -2.65% in one year.

Myriad Genetics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -14.53%.

The current PE Ratio of Myriad Genetics is ―. Myriad Genetics’s PEG ratio is ―.

In the last 12 months, Myriad Genetics had revenue of 837.60M and earned -127.30M in profits. Earnings per share was -1.41.

In the last 12 months, operating cash flow was -22.60M and capital expenditures -27.40M, giving a free cash flow of -50.00M billion.

Myriad Genetics pays an annual dividend of $1.75, resulting in a dividend yield of ―

Myriad Genetics upcoming earnings date is Nov 4, 2025, TBA (Confirmed).

Myriad Genetics as a current ratio of 1.82, with Debt / Equity ratio of 39.84%

In the past 12 months, Myriad Genetics has paid 3.80M in taxes.

Myriad Genetics EV to EBITDA ratio is -21.51, with an EV/FCF ratio of -33.33.

Myriad Genetics has $74.40M in cash and marketable securities with $154.60M in debt, giving a net cash position of $80.20M billion.

Gross margin is 70.44%, with operating margin of -14.74%, and net profit margin of -15.20%.

The average price target for Myriad Genetics is $7.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy